- Biopsy company Angle said it had gotten positive results from a pilot study of technology that harvests fetal cells from the peripheral blood of pregnant women to detect fetal abnormalities.

The results were being presented on Monday at the 6th Annual Advances in Prenatal Diagnostics conference in Cambridge, Massachusetts.

The company's so-called Parsortix system provided a more comprehensive diagnosis of fetal abnormalities for mothers at risk of an affected pregnancy, according to founder and chief executive Andrew Newland.

'Angle's product-based approach to liquid biopsy enables us to leverage partnerships with third parties, which we are developing in the NIPT space, an established and fast-growing large scale market,' Newland said.

At 2:12pm: [LON:AGL] Angle PLC share price was +3p at 42.5p

Story provided by